SANTA CLARA, Calif.--(BUSINESS WIRE)--XenoPort, Inc. (Nasdaq:XNPT) announced today preliminary results from a Phase 2 clinical trial that evaluated the safety and tolerability of arbaclofen placarbil (AP), also known as XP19986, when administered without titration to patients with acute back spasms. All doses of AP were safe and generally well tolerated.
